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during treatment of acute lymphoblastic leukemia (ALL) in
childhood. METHODS: Patients were age ﬁve years or older at
time of study and enrolled in Dana Farber Cancer Institute 95-
001 clinical trial. Parents-of-patients and clinicians, blinded to
each other, completed self-administered HUI questionnaires at
four assessment points during treatment: Induction of remission,
CNS prophylaxis, intensiﬁcation, and maintenance. Agreement
between parents and clinicians, for HUI3 single-attribute and
overall health-related quality of life (HRQL) utility scores, was
assessed using a single-measure two-way mixed model intra-class
correlation coefﬁcient (ICC) and paired t-test. Mean differences
in single-attribute and HRQL scores >0.05 and >0.03, respec-
tively, are clinically important. Statistical signiﬁcance was set at
p < 0.05. ICC results were interpreted as follows: >0.50 strong
agreement; 0.35–0.50 moderate agreement; 0.20–0.34 weak
agreement; 0.00–0.19 negligible agreement. RESULTS: There
were 375 patients who were surveyed (55.2% males). The
number of pairs of parent and clinician assessments varied by
assessment point (minimum = 104, maximum = 180). There was
moderate or better agreement between raters (p < 0.05) at all
assessment points for ambulation (ICC = 0.51–0.84) and pain
(ICC = 0.39–0.84). Weak or better agreement (p < 0.05) was
observed at all assessment points for vision (ICC = 0.23–0.79),
and emotion (ICC = 0.22–0.69). Inter-rater agreement for HRQL
ranged from weak to moderate (ICC = 0.31–0.50, p < 0.05).
There was no signiﬁcant agreement (p > 0.05) for dexterity at
any assessment point (ICC = 0.05–0.16) and for cognition at
Induction (ICC < 0.01). The mean difference (clinician minus
parent) was clinically important for HRQL (difference = 0.07, p
= 0.01) at Maintenance. CONCLUSIONS: Inter-rater agreement
varies, from none to strong, by both type of utility score and
assessment point. A clinically important mean difference in
HRQL scores was observed. Parent and clinician reports should
not be considered interchangeable. The results are consistent
with studies of ALL patients assessed after completion of
therapy.
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OBJECTIVES: The ﬁve-year mortality rate for a population of
adult brain tumor patients is typically high (≥50%). Tumor grade
is a well-known predictor for mortality: low-grade (LG) tumors
are associated with lower mortality rates than are high-grade
(HG) tumors. METHODS: Prospective study of consecutive
patients newly diagnosed with primary brain tumors attending
a single regional centre. A cross-sectional survey collected base-
line health status assessments for each patient after diagnosis,
and in most cases surgery, but before radiotherapy or chemother-
apy. Each participating patient completed a Health Utilities
Index (HUI) Mark 2 (HUI2) and Mark 3 (HUI3) 15-item self-
complete questionnaire, prior to encounter with assessing physi-
cian. The assessing physician, blind to patient’s assessment,
recorded a Karnofsky Performance Score (KPS) and a Mini-
Mental Status Examination (MMSE) score. The life status for
each patient was determined for the ﬁve-year period after assess-
ment. Proportional hazards models estimated the IHOD for dif-
ferences of: 0.10 in HUI utility scores; ten units in KPS; and ﬁve
units in MMSE. Statistical signiﬁcance was set at the 5% level.
RESULTS: HUI2 self-care was the only health status measure
associated with a signiﬁcant IHOD for LG tumors (n = 25): a
decrease of 0.10 in HUI2 self-care score being associated with a
30% IHOD (p = 0.023). Among patients with HG tumors (n =
56), 3 measures were independently signiﬁcant: KPS (20%
IHOD, p = 0.022); MMSE (26% IHOD, p = 0.015) and HUI3
dexterity (18% IHOD, p = 0.035). Two measures, together, were
signiﬁcant among HG patients: MMSE (29% IHOD, p = 0.007)
and HUI3 dexterity (20% IHOD, p = 0.020). CONCLUSION:
Only HUI measures were signiﬁcant predictors of IHOD for both
LG and HG patients. MMSE and HUI3 dexterity, in combina-
tion, were signiﬁcant predictors for HG patients. The latter is
evidence that patient- and physician-reported measures provide
important complementary types of information.
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OBJECTIVES: To assess economic appraisals of chemotherapy
regimens for metastatic colorectal cancer (mCRC) published in
peer-reviewed journals. METHODS: A PubMed search of
English-language documents published up to October 2004 was
conducted using the search terms: “chemotherapy”, “metasta-
tic”, “colorectal cancer”, and “economic”, “cost-effectiveness”,
or “cost-beneﬁt”. Additional publications were identiﬁed from
references, reviews, and meta-analyses. Publications were
reviewed for information on the type of cost analyses, year of
publication, journal, country, perspective, type of chemotherapy
assessed, data collection methods, sponsorship, and types of sen-
sitivity analyses conducted. RESULTS: Economic analyses were
published on eight regimens. Seven of the 14 published studies
were published from a UK perspective, and 2 each from a French
and a Dutch perspective; no study has been published from the
US perspective. Ten studies were cost-consequences and four
were cost-effectiveness analyses. Limited documentation was
provided on sources of costs for medical resource use. Adjust-
ments for quality of life were considered in sensitivity analyses
in two studies designed to inform guidance by the UK’s National
Institute of Clinical Excellence. Overall, drug costs accounted for
1%–37% of total expenditures for 5-ﬂourauracil + leucovorin
(5FU/LV) regimens, in contrast to 47%–83% of total expendi-
tures for newer combination regimens (e.g., irinotecan + 5FU/LV,
oxaliplatin +5FU/LV, capecitabine). No formal analyses were
published on Avastin (bevacizumab) or Erbitux (cetuximab).
Discounting for future costs and beneﬁts was not done in any
analysis. CONCLUSIONS: Some prominent novel regimens for
mCRC have no publicly available economic appraisal. Among
the few published studies on older regimens, most omit compo-
nents such as quality-of-life adjustments, discounting, and 
transparent statements on data sources for prices that are rec-
ommended in ISPOR’s statement on “Good Research Practices—
Modeling Studies.”
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OBJECTIVE: This study seeks to synthesize and identify gaps in
the economic literature of prostate cancer (PCA). METHODS:
English-language abstracts and articles published between 1990
